PiiO

PiiO is a precision immuno-oncology company focused on the MHC class I antigen presentation pathway to enhance cancer immunotherapy. Spun out from the University of Oxford and the University of Southampton, the company leverages deep expertise in how tumors evade the immune system by downregulating MHC class I molecules. PiiO's platform identifies novel targets and develops small molecule therapeutics designed to restore antigen presentation, effectively turning "cold" tumors "hot" and susceptible to immune attack. The company also develops biomarkers to predict patient response to existing immune checkpoint inhibitors, aiming to personalize cancer treatment. By addressing the fundamental biology of antigen presentation, PiiO seeks to expand the efficacy of immunotherapy across a wide range of solid tumors.